Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group started coverage on shares of Disc Medicine (NASDAQ:IRON) in a research report issued on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $89.00 price target on the stock. Jefferies Financial Group’s target price indicates a potential upside of 74.78% from the stock’s current price.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Wells Fargo & Company started coverage on Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a report on Monday, September 16th. Scotiabank started coverage on Disc Medicine in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $62.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $57.00 target price on shares of Disc Medicine in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $66.40.

Disc Medicine Stock Performance

Shares of IRON stock opened at $50.92 on Wednesday. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The firm has a market capitalization of $1.26 billion, a PE ratio of -15.07 and a beta of 0.59. The stock’s 50-day simple moving average is $48.88 and its 200-day simple moving average is $41.75.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08. Sell-side analysts forecast that Disc Medicine will post -4.19 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank grew its position in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the period. SG Americas Securities LLC boosted its holdings in Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after buying an additional 793 shares during the last quarter. Bleakley Financial Group LLC increased its stake in Disc Medicine by 23.0% during the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock worth $285,000 after buying an additional 856 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Disc Medicine by 3.7% during the second quarter. TD Asset Management Inc now owns 40,732 shares of the company’s stock valued at $1,836,000 after acquiring an additional 1,468 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Disc Medicine in the second quarter valued at approximately $129,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.